 Canonic, a wholly owned subsidiary of Evogene Ltd. NASDAQ: EVGN and TASE: EVGN focused on the development of medical cannabis products, announces today an agreement with Hadasit, Hadassah Medical Center Technology Transfer Company, for pre-clinical studies to support the development of anti-inflammatory medical Cannabis products as part of its Precise product program. The work will be conducted by the laboratory of Prof. Reuven Or in Hadassah Medical Center Ein Kerem, Israel, screening Canonics Cannabis core collection in inflammatory in-vitro models. These studies are expected to support the development of Canonics unique Cannabis varieties with anti-inflammatory properties. 